Oral L-DOPA/Carbidopa

About Snyder Biomedical

Snyder Biomedical is pioneering a novel, oral therapeutic approach for neovascular age-related macular degeneration (nAMD) by repurposing L-DOPA to activate the GPR143 receptor. This mechanism aims to naturally downregulate pathologic VEGF in the eye, potentially reducing the treatment burden of frequent intraocular injections. The company has generated promising proof-of-concept clinical data and is advancing toward a Phase 2 prevention trial. Founded by an ophthalmologist and a chemical engineer, Snyder Biomedical holds key intellectual property licensed from the University of Arizona and is seeking a pharmaceutical partner for further development.

About Snyder Biomedical

Snyder Biomedical is pioneering a novel, oral therapeutic approach for neovascular age-related macular degeneration (nAMD) by repurposing L-DOPA to activate the GPR143 receptor. This mechanism aims to naturally downregulate pathologic VEGF in the eye, potentially reducing the treatment burden of frequent intraocular injections. The company has generated promising proof-of-concept clinical data and is advancing toward a Phase 2 prevention trial. Founded by an ophthalmologist and a chemical engineer, Snyder Biomedical holds key intellectual property licensed from the University of Arizona and is seeking a pharmaceutical partner for further development.

Therapeutic Areas